Greater baseline disease pruritus and quality of life impairment are associated with higher rates of super response to dupilumab in patients with AD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback